# Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

> **NCT04505254** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **BIOLOGICAL:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04505254
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-25
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04505254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04505254, "Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04505254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*